Cannabis Science, Inc., (OTC PINK: CBIS), a U.S. Company specializing in the development of cannabis-based medicines, today announced the completion and unveiling of their wholly-owned animal product subsidiary Equi-Pharm's e-commerce website at www.equi-pharm.com for Nation-Wide sales of Equi-Pharm's Quality Animal Care Products.

The site will allow animal owners across the country easy access to the Equi-Pharm quality lineup of products. In the site's unveiling, the company's first Hemp infused product is available for horse owners. Equi-Sheen HP, a medicated grooming product for Horses, is now ready for shipment directly from the Equi-Pharm shipping facility in Shelbyville, TN.

This milestone allows Equi-Pharm to broaden its reach across the nation and unveil its New Hemp infused products to the Equine and Pet markets in an expedited time frame.

Web sales grew by about 81% from 2010 to 2014 and have continued to grow rapidly, according to a report released by the U.S. Commerce Department. This growth in web-based consumer spending patterns complements the company's move to an e-commerce platform.

"We are excited to announce the launch of Equi-Pharm's website. While in the past, Equi-Pharm has served a very localized, niche market, it will now be able to reach consumers around the globe with our high quality grooming and healthcare product lines," said Cannabis Science CEO, Raymond C. Dabney. "We are in the process of launching ten unique hemp and CBD-infused animal products in the very near future, and we feel our e-commerce site is a great medium to keep overhead low and reach the largest audience possible."

About Equi-Pharm, LLC

Founded in 1997 in Shelbyville, TN, Equi-Pharm develops, formulates and markets horse and pet grooming aids and topical remedies using high quality ingredients in the U.S.A. The company specializes in utilizing natural ingredients to provide safe and impactful health benefits to animals. Equi-Pharm, LLC is proud to still call Shelbyville, TN home.

About Cannabis Science, Inc.

Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Forward-Looking Statements This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.